Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acthar Gel in RA with Persistently Active Disease
NCT02919761Phase 4Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Nov 2016
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 4, randomised, double-blind trial of repository corticotropin injection in rheumatoid arthritis (RA) (3 arms), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoints: Low Disease Activity at 12 weeks and Maintenance of Low Disease Activity at 24 weeks. Started Nov 2016; status: completed.
02
Drugs
repository corticotropin injection
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02919761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919761.